Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe Denner can replace Lars as Chairman!?
Wish we would have done this years ago prior to atherosclerosis great raid on the treasury:
https://www.cnbc.com/2022/05/16/intel-shareholders-reject-executive-pay.html
He can’t have bought much since he has to file on every increment of 1% of outstanding that he acquires ~4 mil. He sure has been passive for an activist.
FFS Somehow I lost your response, please repeat
FFS, I have a couple of TA issues I’d like to discuss with you off site if possible. If you are amenable, my email is invest2992@yahoo.com thanx.
marjac, it pains me to say I had 39k shares on that fateful day. So I qualify as a 6 figure loser.
marjac, thanks for the response. On a somewhat related note, we are in the throes of another adverse price reaction to an unexpectedly bad 1st quarter report. I will just make the observation that much of this is due to managements total lack of 1st quarter communications with shareholders and Wall Street in an effort to manage expectations and to set the stage for this report. This is the most inept management I have ever witnessed butchering their own company and product. From Lars on down, every one should be removed
Marjac, I know you are working hard to meet your deadline and I don’t want to add any pressure on you, but from where I stand today (substantially under water) I view your effort as the last best chance to revive this stock now in its final death throes. If it is of any help, I personally think your chances of winning at the SC level are greater than the slim odds everyone gives your effort. Good luck and God bless.
Finally, company representative: Depak Bhatt. Finally.
I hope Denner is standing in the pits catching these shares in a bushel basket.
I would take a $5 bid to take this private.
What can we shareholders do the get rid of this management effective immediately?
Maybe some minor catalysts in EU, but the major catalysts with indefinite time frames are the Health Net suit and Marjac’s petition to the Supreme Court. Victories in either/both would have a major price impact. But both are long shots.
What was your estimate of revenue? I assume the shortfall in revenues reflects a runoff of inventories at the distribution and retail levels.
What the hell is Denner doing? Selling his shares?
Why do you mindlessly keep posting your AMRN chart?
Do you think no one here is aware of the stocks price action?
At least FFS gives us his TA analysis.
Anyone else having trouble with yahoo not loading?
Have you tried to get a tier exemption?
We are a pill-popping society, we'd rather take a pill than change our way of living. That said, I highly recommend considering Repatha which lowered my LDL from just over 100 as I remember to the low teens!
whatever happened to hindukush, he was such a valued poster
Can we get Bhatt and Mason to draft the final response? it would be worth the cost.
Sleven then how do we get a positive final decision?
F'ing Nissen. His license to practice medicine should be taken. He does not know the meaning of "do no harm." hundreds of brits will needlessly succumb to CVD because they were denied Vazkepa because NICE refused to approve due to Nissen's prejudicial, small-minded and malignant testimony.
That sounds like data mining and would devalue the reported results if they are just “repairing” participants.
why would you expand the trial to 39000, unless you were fairly certain the ongoing results were positive?
what say you now as to chart prospects?
I hope you get a response, this is all gobelty-gook to me and I was considering asking for help from our two experts.
74500
Why is everything manyana with Amarin? NICE, China, MITIGATE, combo pill, European applications? What else? Denner?
So is mitigate on or off?
Interesting cause of heart problems:
https://articles.mercola.com/sites/articles/archive/2022/03/30/root-canal-infection.aspx?ui=ff340c8dbd45cc819d4a24e4c8404772abc3ca8f52ef1a47742a0bc8bfe56f7a&sd=20150731&cid_source=dnl&cid_medium=email&cid_content=art3ReadMore&cid=20220330&mid=DM1143170&rid=1447760841
Raf and Capt, the Friday power pair, thanks to you both for your efforts on behalf of your fellow shareholders. Hopefully, today's script report is the start of a new trend. it should be given the superiority of V to L and the questionable bioequivalence of gv.
unbelievable. let's hope it is the start of a new trend.
I'm having brain freeze, but what is this "Amarin is anticipating cardiovascular outcomes data this fall" Sorry, totally missed the date on the article. Why are we posting 2018 sh*t
marjac, I'm getting way ahead of myself, but assuming our EPADI efforts are successful and generics must pay damages to AMRN is there any way EPADI can dictate the use of the proceeds to their benefit, which I would perceive to be the open market repurchase of outstanding shares. I would hate to see our efforts diverted to the benefit and pockets of Amarin's robber managers.
given that so few writs are granted, would you file a reply if you were Hikma? Their defense to the fraud seems difficult at best, can only argue standing and even that should be difficult if the courts follow law and precedent.
marjac, assuming our petition for a writ of certiorari is filed May 16 (hopefully a few days earlier) what is the soonest we could expect a decision by the court? what is the typical response time if there is one?
i thought it is Bhatt
Institutions vote their proxies in one of two ways (actually 3 if you include selling the company stock if they don"t like the prospects of the issues at hand,i.e. voting with their feet). 1) they simply vote on each issue as recommended by management, or 2) they vote according to the proxy consultant they subscribe to, making them appear to be exercising due diligence. Few if any spend any time researching the issues and fewer still have policies that guide their voting.